European Commission’s Pharmaceutical Strategy to Tackle Unmet Kidney Care Needs
The ISN welcomes the European Commission’s “Pharmaceutical Strategy for Europe,” released on November 25, 2020.
Aspects of the strategy’s objectives are reflective of ISN’s vision of equitable access to kidney health and include:
- Re-thinking policies to stimulate innovation in areas of need, and patient-centered, health system-oriented pharmaceutical innovation to address long-term care settings.
- Investing in research and development to evolve innovative medicines and treatments to be made accessible to disadvantaged groups.
In a press release, biotech products to treat chronic conditions such as renal failure in patients with anemia were highlighted milestones of significant progress in treatments in the EU over the past 20 years.
The ISN looks forward to working with partners and the EU institutions to collectively advance kidney care across Europe.
